MDH1B: A Potential Drug Target and Biomarker for Melanoma (G130752)

MDH1B: A Potential Drug Target and Biomarker for Melanoma

Melanoma is one of the most aggressive forms of skin cancer, with a high incidence rate and a poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for melanoma remains poor, with a five-year survival rate of only around 45%. The development of drug resistance and the lack of effective new treatments have made the treatment of melanoma a significant challenge.

One potential solution to this problem is targeting the MDH1B gene, which has been shown to be involved in the development and progression of melanoma. The MDH1B gene is a promising target for drug development due to its involvement in the development of drug resistance and its expression in various types of cancer.

The MDH1B gene is a member of the PIK3CA gene family, which is known for its role in the development and progression of various types of cancer. The PIK3CA gene family has been implicated in the development of melanoma due to its association with the development of drug resistance and the inhibition of the DNA damage response.

Research has shown that the MDH1B gene is involved in the development and progression of melanoma by inhibiting the DNA damage response and promoting the development of drug resistance. This is accomplished through the inhibition of the DNA damage response, which leads to the accumulation of mutations in the genome, leading to the development of drug resistance.

Furthermore, the MDH1B gene has also been shown to be involved in the regulation of the cell cycle, which is a critical aspect of the development and progression of cancer. The inhibition of the DNA damage response and the cell cycle have been shown to lead to the growth arrest and apoptosis of cancer cells, which can be an effective strategy for cancer treatment.

Due to its involvement in the development and progression of melanoma, the MDH1B gene has been identified as a potential drug target. Small molecules have been shown to be effective in inhibiting the activity of the MDH1B gene, leading to the inhibition of its function in the development and progression of melanoma.

In addition, the MDH1B gene has also been shown to be involved in the regulation of the immune response, which is a critical aspect of cancer immune surveillance. The inhibition of the DNA damage response and the cell cycle have been shown to enhance the immune response and promote the destruction of cancer cells.

Overall, the MDH1B gene is a promising target for drug development due to its involvement in the development and progression of melanoma. The inhibition of its function may be an effective strategy for the treatment of melanoma and other types of cancer. Further research is needed to fully understand the role of the MDH1B gene in the development and progression of cancer and to develop effective treatments.

Protein Name: Malate Dehydrogenase 1B

The "MDH1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MDH1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK | MELTF | MELTF-AS1 | Membrane-Bound Protein Tyrosine Phosphatases (rPTPs) | Membrane-spanning 4-domains subfamily A member 4A | MEMO1 | MEMO1P1 | MEMO1P4 | MEMO1P5